A pocket guide to fluoxetine treatment Review article
Article Sidebar
Published:
Mar 1, 2026
Keywords:
fluoxetine, SSRI, depression, antidepressant
Main Article Content
Abstract
Fluoxetine was the first drug from the serotonin reuptake inhibitor group to be approved for marketing in the USA by the Food and Drug Administration in December 1987, and it was introduced to the market in January 1988. It has been available in Poland since the early 1990s. Despite its long-term availability on the market, we are still discovering new clinical applications for fluoxetine and learning how to better use this drug in the daily work of psychiatrists, in order to fully utilize its strengths and areas in which it has advantages over other antidepressants, and to conduct effective and safe pharmacotherapy while avoiding risks.
Article Details
How to Cite
Antosik-Wójcińska, A. Z. (2026). A pocket guide to fluoxetine treatment. Medycyna Faktow (J EBM), 19(4(69), 551-556. https://doi.org/10.24292/01.MF.0425.10
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. Charakterystyka produktu leczniczego. Bioxetin.
2. Patejuk-Mazurek I. Fluoksetyna – wykorzystać potencjał leku. Medycyna Faktów. 2024; 18(4): 481-5.
3. Lew-Starowicz M. Leki przeciwdepresyjne a zaburzenia pożądania – jak zapobiegać, jak leczyć? Psychiatria po Dyplomie. 2014; 01.
4. Bancroft J. Sexual arousal and response – the psychosomatic circle In: Bancroft J. Human Sexuality and Its Problems. Elsevier, Edynburg, Londyn, Nowy Jork, Oxford, Philadelphia, St Louis, Sydney, Toronto 2009: 55-143.
5. Stahl SM. Podstawy psychofarmakologii. Leki przeciwdepresyjne. Wydanie trzecie. Via Medica, Gdańsk 2010: 89-95.
6. Clayton AH, Pradko JF, Croft HA et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63: 357-66.
7. Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006; 67: 736-46.
8. Wróbel M, Mosiołek A. Dysfunkcje seksualne w przebiegu zaburzeń depresyjnych. Psychiatria. 2018; 15(1): 39-44.
9. Jaykaran C, Bhardwaj P, Kantharia ND et al. Effect of fluoxetine on some cognitive functions of patients of depression. Indian J Psychol Med. 2009; 31: 24-9.
10. Cassano GB, Puca F, Scapicchio PL et al.; Italian Study Group on Depression in Elderly Patients. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry. 2002; 63: 396-402.
11. Doraiswamy PM, Krishnan KR, Oxman T et al. Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci. 2003; 58: M1137-44.
12. Maalouf F, Bakhti R, Tamim H et al. Neurocognitive predictors of clinical improvement in selective serotonin reuptake inhibitor-treated adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2018; 28: 387-94.
13. Shehab AA, Brent D, Maalouf FT. Neurocognitive changes in selective serotonin reuptake inhibitors-treated adolescents with depression. J Child Adolesc Psychopharmacol. 2016; 26: 713-20.
14. Casarotto PC, Girych M, Fred SM et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021; 184: 1299-313.
15. Song T, Wu H, Li R et al. Repeated fluoxetine treatment induces long-lasting neurotrophic changes in the medial prefrontal cortex of adult rats. Behav Brain Res. 2019; 365: 114-24.
16. Ramachandrappa S, Gorrigan RJ, Clark AJ et al. The melanocortin receptors and their accessory proteins. Front Endocrinol (Lausanne). 2013; 4: 9.
17. Skrzypulec-Plinta V, Antosik-Wójcińska A. Postępowanie z pacjentką w wieku menopauzalnym w praktyce lekarza podstawowej opieki zdrowotnej. Neuropsychiatria. Przegląd Kliniczny. 2021; 13: 44-51.
18. Azizi M, Khani S, Kamali M et al. The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials. Iran J Med Sci. 2022; 47(3): 173-93.
19. Amsterdam J, Garcia-Espana F, Fawcett J et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999; 55(1): 11-7.
20. Kofler T, Hess S, Moccetti F et al. Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction – A Systematic Review and Meta-analysis of Randomized Trials. CJC Open. 2021; 3(1): 101-8. http://doi.org/10.1016/j.cjco.2020.09.005.
21. Ahmed B, Mondragon J, Sheldon M et al. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study. Cardiovasc Revasc Med. 2017; 18(6): 431-5. http://doi.org/10.1016/j.carrev.2017.04.012.
22. Ling H, Fu S, Xu M et al. Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials. Quant Imaging Med Surg. 2024; 14(2): 1451-65. http://doi.org/10.21037/qims-23-1029.
23. Ferrari R, Ford I, Fox K et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. The Lancet. 2020; 396(10254): 830-8. http://doi.org/10.1016/S0140-6736(20)31790-6.
24. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007; 49(10): 1027-34. http://doi.org/10.1016/j.jacc.2006.10.067.
2. Patejuk-Mazurek I. Fluoksetyna – wykorzystać potencjał leku. Medycyna Faktów. 2024; 18(4): 481-5.
3. Lew-Starowicz M. Leki przeciwdepresyjne a zaburzenia pożądania – jak zapobiegać, jak leczyć? Psychiatria po Dyplomie. 2014; 01.
4. Bancroft J. Sexual arousal and response – the psychosomatic circle In: Bancroft J. Human Sexuality and Its Problems. Elsevier, Edynburg, Londyn, Nowy Jork, Oxford, Philadelphia, St Louis, Sydney, Toronto 2009: 55-143.
5. Stahl SM. Podstawy psychofarmakologii. Leki przeciwdepresyjne. Wydanie trzecie. Via Medica, Gdańsk 2010: 89-95.
6. Clayton AH, Pradko JF, Croft HA et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63: 357-66.
7. Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006; 67: 736-46.
8. Wróbel M, Mosiołek A. Dysfunkcje seksualne w przebiegu zaburzeń depresyjnych. Psychiatria. 2018; 15(1): 39-44.
9. Jaykaran C, Bhardwaj P, Kantharia ND et al. Effect of fluoxetine on some cognitive functions of patients of depression. Indian J Psychol Med. 2009; 31: 24-9.
10. Cassano GB, Puca F, Scapicchio PL et al.; Italian Study Group on Depression in Elderly Patients. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry. 2002; 63: 396-402.
11. Doraiswamy PM, Krishnan KR, Oxman T et al. Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci. 2003; 58: M1137-44.
12. Maalouf F, Bakhti R, Tamim H et al. Neurocognitive predictors of clinical improvement in selective serotonin reuptake inhibitor-treated adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2018; 28: 387-94.
13. Shehab AA, Brent D, Maalouf FT. Neurocognitive changes in selective serotonin reuptake inhibitors-treated adolescents with depression. J Child Adolesc Psychopharmacol. 2016; 26: 713-20.
14. Casarotto PC, Girych M, Fred SM et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021; 184: 1299-313.
15. Song T, Wu H, Li R et al. Repeated fluoxetine treatment induces long-lasting neurotrophic changes in the medial prefrontal cortex of adult rats. Behav Brain Res. 2019; 365: 114-24.
16. Ramachandrappa S, Gorrigan RJ, Clark AJ et al. The melanocortin receptors and their accessory proteins. Front Endocrinol (Lausanne). 2013; 4: 9.
17. Skrzypulec-Plinta V, Antosik-Wójcińska A. Postępowanie z pacjentką w wieku menopauzalnym w praktyce lekarza podstawowej opieki zdrowotnej. Neuropsychiatria. Przegląd Kliniczny. 2021; 13: 44-51.
18. Azizi M, Khani S, Kamali M et al. The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials. Iran J Med Sci. 2022; 47(3): 173-93.
19. Amsterdam J, Garcia-Espana F, Fawcett J et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999; 55(1): 11-7.
20. Kofler T, Hess S, Moccetti F et al. Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction – A Systematic Review and Meta-analysis of Randomized Trials. CJC Open. 2021; 3(1): 101-8. http://doi.org/10.1016/j.cjco.2020.09.005.
21. Ahmed B, Mondragon J, Sheldon M et al. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study. Cardiovasc Revasc Med. 2017; 18(6): 431-5. http://doi.org/10.1016/j.carrev.2017.04.012.
22. Ling H, Fu S, Xu M et al. Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials. Quant Imaging Med Surg. 2024; 14(2): 1451-65. http://doi.org/10.21037/qims-23-1029.
23. Ferrari R, Ford I, Fox K et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. The Lancet. 2020; 396(10254): 830-8. http://doi.org/10.1016/S0140-6736(20)31790-6.
24. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007; 49(10): 1027-34. http://doi.org/10.1016/j.jacc.2006.10.067.